DVAX Dynavax Technologies Corporation

10.62
+0.13  (+1%)
Previous Close 10.49
Open 10.39
Price To Book 6.85
Market Cap 665783496
Shares 62,691,478
Volume 754,857
Short Ratio
Av. Daily Volume 1,261,364

SEC filingsSee all SEC filings

  1. 8-K - Current report 181209062
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163082
  3. 8-K - Current report 181162975
  4. 8-K - Current report 181131624
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181118417

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 update at ESMO 2018 noted ORR 70%.
SD-101 + Pembrolizumab
Melanoma and head and neck squamous cell carcinoma (HNSCC)
CRL February 25, 2013 and November 14, 2016. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval. Final approval announced November 9, 2017.
HEPLISAV-B
Hepatitis B
Phase 2a trial did not meet primary endpoint - November 29, 2018.
AZD1419
Asthma
Phase 1 safety and biomarker data due 4Q 2018.
DV281
Non-small Cell Lung Cancer (NSCLC)

Latest News

  1. Edited Transcript of DVAX earnings conference call or presentation 5-Nov-18 9:30pm GMT
  2. Why Dynavax Technologies Corporation Fell 20.2% in October
  3. Dynavax Technologies: 3Q Earnings Snapshot
  4. Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
  5. Don't Waste Your Money on Penny Stocks; These 3 Stocks Are Better Buys
  6. Dynavax to Host Third Quarter 2018 Financial Results Conference Call
  7. Dynavax Technologies (DVAX) Q3 Earnings Preview: What to Watch Ahead of the Release
  8. Dynavax (DVAX) Catches Eye: Stock Jumps 9.8%
  9. Why American Railcar Industries, PetMed Express, and Dynavax Technologies Jumped Today
  10. Why Dynavax Technologies Corporation Is Surging Today
  11. Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress
  12. Medical Companies You Need to Have on Your Radar
  13. Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
  14. Dynavax Technologies and Quantum Leap Healthcare Collaborative Announce Selection of SD-101 Combined with KEYTRUDA® (pembrolizumab) in the I-SPY 2 TRIAL For Breast Cancer
  15. The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
  16. Major Biotech Announcements Moving the Market
  17. ARWR Stock Sinks After Signing a Big Collaboration Deal
  18. Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Oncology 2018 Congress
  19. Why Dynavax Technologies Corporation Stock Struggled in September

SEC Filings

  1. 8-K - Current report 181209062
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163082
  3. 8-K - Current report 181162975
  4. 8-K - Current report 181131624
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 181118417
  6. 8-K - Current report 181081704
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998087
  8. 8-K - Current report 18997943
  9. S-8 - Securities to be offered to employees in employee benefit plans 18889452
  10. 8-K - Current report 18880016